Home > Oncology > ASCO 2019 > Melanoma > Long term quality of life with nivolumab, or in combination (ipilimumab) in advanced melanoma

Long term quality of life with nivolumab, or in combination (ipilimumab) in advanced melanoma


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
ASCO 2019
Trial
Phase 3, CheckMate 067
Medical writer: Dr. Rachel H. Giles Two new analyses of CheckMate 067 data determined that quality of life (QoL) was maintained throughout the course of treatment (either nivolumab alone or with ipilimumab), on long-term (4 year) follow-up and, importantly, that these benefits persisted when the patients were off therapy [1,2]. The phase 3 CheckMate 067 was a Phase 3, double-blind, randomised trial that evaluated the combination of nivolumab plus ipilimumab (n=314) or nivolumab monotherapy (n=316) vs. ipilimumab monotherapy (n=315) in a total of 945 patients with previously untreated advanced melanoma. An analysis exploring long-term quality of life (QoL) and symptom burden found that QoL was maintained during the treatment-free interval (TFI) – the period where a patient is off study treatment and free of subsequent therapy – in patients with previously untreated unresectable or metastatic melanoma following discontinuation of therapy with nivolumab or niv...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on